BioStock interviews Christina Herder new CEO in Idogen
Idogen AB (publ) is a company developing tolerogenic cell therapies to treat conditions or diseases caused by an unwanted immune response in the patient. The candidate drug ItolDC-028 will within short be tested for the first time in patients with haemophilia who have developed antibodies against their vital factor VIII treatment. The aim is to make the patients responsing again to their factor VIII treatment.
Christina Herder took office as acting CEO on September 1 and is giving her first interview with BioStock.
During the autumn, Christina is expecting a number of key events which are mentioned in the interview;
- The first patient will be included in the study and will receive its first treatment
- The Clinical Trial Application will be submitted in additional countries outside of the Nordics
- We will also increase our external focus by publishing scientific articles, participate at medical conferences as well as in partnering events
It feels great to lead the company during this very intense and transforming autumn, the most important during the company’s history” say Christina Herder, acting CEO.
Read the interview in its entirety here https://www.biostock.se/en/2022/09/idogens-acting-ceo-talks-about-the-plans-for-the-autumn/
For further information, please contact:
Christina Herder, Acting CEO, Idogen AB
Phone: +46 70 374 71 56
Email: christina.herder@idogen.com
Certified Adviser:
The companies Certified Adviser is Vator Securities AB. Contact information: Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm, Email: ca@vatorsec.se. Tel: +46 (0)8-580 065 99
The information was submitted for publication, through the agency of the contact persons set out above, on 13 September 2022 at 10:01 CET.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own
cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care. More information about Idogen is available via https://www.idogen.com